Whales with a lot of money to spend have taken a noticeably bearish stance on Iovance Biotherapeutics.
Looking at options history for Iovance Biotherapeutics (NASDAQ:IOVA) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 17% of the investors opened trades with bullish expectations and 82% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $589,675 and 5, calls, for a total amount of $608,250.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $15.0 for Iovance Biotherapeutics, spanning the last three months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of Iovance Biotherapeutics stands at 1138.5, with a total volume reaching 11,833.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Iovance Biotherapeutics, situated within the strike price corridor from $10.0 to $15.0, throughout the last 30 days.
Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | CALL | SWEEP | BEARISH | 12/20/24 | $2.55 | $2.45 | $2.45 | $14.00 | $220.5K | 8 | 602 |
| IOVA | CALL | TRADE | BEARISH | 12/20/24 | $2.55 | $2.4 | $2.4 | $14.00 | $144.0K | 8 | 602 |
| IOVA | CALL | SWEEP | BULLISH | 06/21/24 | $2.5 | $2.3 | $2.5 | $10.00 | $125.0K | 3.0K | 20 |
| IOVA | PUT | SWEEP | BULLISH | 09/20/24 | $4.2 | $4.0 | $4.0 | $15.00 | $78.8K | 578 | 197 |
| IOVA | PUT | SWEEP | BEARISH | 09/20/24 | $1.55 | $1.4 | $1.55 | $10.00 | $74.7K | 854 | 231 |
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
In light of the recent options history for Iovance Biotherapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Iovance Biotherapeutics Standing Right Now?
- Currently trading with a volume of 11,609,305, the IOVA's price is down by -17.77%, now at $11.06.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 88 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iovance Biotherapeutics with Benzinga Pro for real-time alerts.